BioSight
Companies
Sol-Gel Technologies Ltd. logo

SLGL

NASDAQNESS ZIONA
Sol-Gel Technologies Ltd.

Sol-Gel Technologies develops topical dermatology treatments, with two FDA-approved products (Twyneo for acne and Epsolay for rosacea) and two clinical-stage candidates (SGT-610 for basal cell carcinoma prevention in Gorlin Syndrome and SGT-210, a topical EGFR inhibitor platform). The company uses a gel-based delivery technology to enable local drug action with limited systemic exposure.

Price history not yet available for SLGL.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar